{"id":390946,"date":"2017-07-17T00:00:00","date_gmt":"2017-07-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0038-2017-biopharma-psoriasis-treatment-algorithms-claims-data-analysis-us-2017\/"},"modified":"2026-05-09T05:38:25","modified_gmt":"2026-05-09T05:38:25","slug":"algoim0038-2017-biopharma-psoriasis-treatment-algorithms-claims-data-analysis-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0038-2017-biopharma-psoriasis-treatment-algorithms-claims-data-analysis-us-2017\/","title":{"rendered":"Psoriasis | Treatment Algorithms | Claims Data Analysis | US | 2017"},"content":{"rendered":"<p>MARKET OUTLOOK<br \/>\nThe psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe population who cannot be adequately controlled with topical agents. The dominance of the TNF-alpha inhibitors and IL-12\/23 Stelara (Janssen) is being challenged by the introduction of the highly effective IL-17 inhibitors. In particular, the uptake of Novartis\u2019 Cosentyx has been remarkable in the first two years of its launch, but faces competition from the new IL-17 inhibitors, in particular Eli Lilly\u2019s Taltz. In addition, Celgene\u2019s oral PDE-4 inhibitor Otezla has been approved for over three years in the United States and is gaining steady uptake in early lines of therapy.<br \/>\nQUESTIONS ANSWERED<\/p>\n<ul>\n<li>\u00b7 What patient share do key therapies and brands garner by line of therapy in newly diagnosed psoriasis patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed psoriasis patients?<\/li>\n<li>\u00b7 How have non-TNF-alpha inhibitor biologics and Otezla been integrated into the treatment algorithm?<\/li>\n<li>\u00b7 What proportion of psoriasis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>\u00b7 What percentage of psoriasis patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>\u00b7 What are the product-level compliance and persistency rates among drug-treated patients with psoriasis?<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390946","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390946\/revisions"}],"predecessor-version":[{"id":394070,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390946\/revisions\/394070"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}